Favoritar este trabalho
Como citar esse trabalho?
Resumo

As a part of Medicines for Malaria Venture’s efforts to deliver a clinical candidate that could be used as a Single Encounter Radical Cure and Prophylaxis (SERCaP) for Malaria, several compound libraries were screened against Plasmodium falciparum. The Screening Actives were prioritized based on their potency, physicochemical properties, and structural alerts. Then, top prioritized compounds were resynthesized or purchased to confirm the activity against P falciparum.
Once the activity of the Screening Actives is confirmed, the Hit Compounds are profiled in depth, to prioritize work on series that are more likely to progress to Lead Optimization Stage. For instance, throughout our work we found that besides testing the compounds against sensitive and resistant strains, we should also evaluate the propensity of generating resistance by determining the Minimum Inoculum for Resistance. Herein, we will present some of our progress towards the Validation of Hit Compounds.

Compartilhe suas ideias ou dúvidas com os autores!

Sabia que o maior estímulo no desenvolvimento científico e cultural é a curiosidade? Deixe seus questionamentos ou sugestões para o autor!

Faça login para interagir

Tem uma dúvida ou sugestão? Compartilhe seu feedback com os autores!

Instituições
  • 1 UNICAMP
  • 2 Medicines for Malaria Venture
  • 3 Universidade Estadual de Campinas
  • 4 USP - São Carlos
  • 5 Universidade de São Paulo
  • 6 MMV
Eixo Temático
  • 2. Medicinal Chemistry of Synthetic Compounds
Palavras-chave
Drug Discovery
Drug Development
hit validation
malária
SAR exploration